beta
Trial Radar AI
Clinical Trial NCT07114991 for Obesity &Amp; Overweight, Sedentary Behaviors, Cardiometabolic Risk, Physical Inactivity is active, not recruiting. See the Trial Radar Card View and AI discovery tools for all the details. Or ask anything here.
One trial matched filter criteria
Card View
Back to Search

E-Bike Commuting and Health in Overweight College Students

Active, not recruiting
Clinical Trial NCT07114991 is an interventional study for Obesity &Amp; Overweight, Sedentary Behaviors, Cardiometabolic Risk, Physical Inactivity that is active, not recruiting. It started on 1 May 2025 with plans to enroll 60 participants. Led by University of Wisconsin, River Falls, it is expected to complete by 30 June 2026. The latest data from ClinicalTrials.gov was last updated on 11 August 2025.
Brief Summary
This study will evaluate the effects of using a pedal-assist electric bicycle (e-bike) for commuting on physical activity, fitness, and health in overweight or obese college students. Participants will be randomly assigned to either a 12-week e-bike commuting intervention or a control group. The study will measure changes in cardiorespiratory fitness, body composition, blood biomarkers, physical activity, and psychological well-being over a 24-week period.
Detailed Description
This randomized controlled trial investigates the effectiveness of e-bike commuting as a strategy to improve cardiometabolic health, physical activity levels, and psychological well-being in college students with a body mass index (BMI) of 25 kg/m² or higher. Eligible participants will be randomized to either a 12-week e-bike intervention group or a control group that continues usual commuting habits. Assessments will occur at baseline (Week 0), post-intervention (Week 12), and follow-up (Week 24). Each assessment will include VO₂peak testing using a graded cycle ergometer protocol, body composition assessment via BodPod, fasting fingerstick blood tests for glucose, cholesterol, and triglycerides, blood pressure and resting heart rate measurement, and self-report questionnaires evaluating motivation, stress, affect, mental health, and academic engagement. Participants will also complete a 30-minute submaximal cycling test during which affective responses will be recorded, and physical activity will be tracked over 7 days. Those assigned to the intervention group will receive a pedal-assist e-bike, helmet, and safety training and will be asked to ride at least four days per week for 12 weeks. The study aims to determine whether e-bike commuting can promote sustained physical activity and improve cardiometabolic and mental health outcomes in a population at risk for early health decline.
Official Title

Effects of Pedal-Assist E-Bike Commuting on Cardiometabolic Health, Physical Activity, and Psychological Well-Being in Overweight College Students

Conditions
Obesity &Amp; OverweightSedentary BehaviorsCardiometabolic RiskPhysical Inactivity
Publications
Scientific articles and research papers published about this clinical trial:
Other Study IDs
  • 2025-101
NCT ID Number
NCT07114991
Start Date (Actual)
2025-05-01
Last Update Posted
2025-08-11
Completion Date (Estimated)
2026-06-30
Enrollment (Estimated)
60
Study Type
Interventional
PHASE
N/A
Status
Active, not recruiting
Keywords
Electric bicycle
Active commuting
Exercise motivation
Health behavior
Physical activity
Overweight
Primary Purpose
Basic Science
Design Allocation
Randomized
Interventional Model
Parallel
Masking
None (Open Label)
Arms / Interventions
Participant Group/ArmIntervention/Treatment
ExperimentalExperimental Group
Participants in this group will receive a pedal-assist electric bicycle (e-bike), helmet, safety training, and cycling computer. They will be instructed to use the e-bike for commuting or transportation at least four days per week for 12 weeks. They will also complete assessments at baseline, Week 12, and Week 24, including fitness testing, body composition, blood testing, surveys, and activity monitoring.
E-bike Commuting
Participants in the intervention group will receive a pedal-assist electric bicycle (e-bike), a helmet, safety training, and a cycling computer. They will be asked to use the e-bike for commuting or personal travel at least four times per week for 12 weeks. E-bike usage will be monitored using a Garmin Edge device. Participants will also complete baseline, 12-week, and 24-week assessments including fitness testing, blood tests, body composition, surveys, and wearable activity monitoring.
No InterventionControl Group
Participants in the control group will maintain their usual commuting and physical activity habits for the 12-week intervention period. They will complete the same assessments as the intervention group at baseline, Week 12, and Week 24.
N/A
Primary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in daily moderate-to-vigorous physical activity (minutes/day)
Physical activity will be measured using a hip-worn ActiGraph GT3X+ accelerometer over 7 consecutive days at baseline, Week 12, and Week 24. The device will be analyzed using validated cut points to determine average daily time spent in moderate-to-vigorous physical activity (MVPA). The primary outcome is the change in MVPA from baseline to Week 24
From enrollment to end of study at 24 weeks.
Change in cardiorespiratory fitness (VO₂peak, mL/kg/min)
Cardiorespiratory fitness will be measured via a graded cycling test using a metabolic cart to determine peak oxygen uptake (VO₂peak). Participants will complete the test at baseline (Week 0), post-intervention (Week 12), and follow-up (Week 24). The primary comparison will be the change in VO₂peak from baseline to Week 12 between the intervention and control groups.
From enrollment to end of study at 24 weeks.
Secondary Outcome Measures
Outcome MeasureMeasure DescriptionTime Frame
Change in body fat percentage
Body composition will be assessed using air displacement plethysmography (BodPod®). Percent body fat will be calculated at baseline, Week 12, and Week 24.
From enrollment to end of study at 24 weeks.
Change in total cholesterol, HDL-C, LDL-C, and triglycerides (mg/dL)
Fasting lipid profiles will be assessed at baseline, Week 12, and Week 24 via fingerstick blood sample. Changes in total cholesterol, HDL, LDL, and triglycerides will be evaluated to assess cardiometabolic risk.
From enrollment to end of study at 24 weeks.
Change in fasting blood glucose (mg/dL)
Fasting blood glucose will be collected via fingerstick and analyzed using a portable blood analyzer. Values will be compared between baseline, Week 12, and Week 24 to determine the impact of the e-bike intervention on glucose regulation.
From enrollment to end of study at 24 weeks.
Change in exercise motivation (BREQ-3 score)
Exercise motivation will be assessed using the Behavioral Regulation in Exercise Questionnaire-3 (BREQ-3) at all three time points. Subscale scores (e.g., intrinsic motivation, external regulation) will be analyzed for changes between baseline, Week 12, and Week 24.
From enrollment to end of study at 24 weeks.
Eligibility Criteria

Eligible Ages
Adult
Minimum Age
18 Years
Eligible Sexes
All
Accepts Healthy Volunteers
Yes
  • Aged 18-29 years
  • Currently enrolled undergraduate or graduate student
  • Body mass index (BMI) ≥25.0 kg/m² (classified as overweight or obese)
  • Self-report of engaging in <150 minutes per week of moderate-to-vigorous physical activity
  • Able and willing to safely ride a bicycle for commuting or transportation purposes
  • Willing to be randomized and complete all study procedures across 24 weeks Able to provide informed consent

  • Current use of a bicycle or e-bike for commuting ≥2 times per week
  • Known cardiovascular, metabolic, or orthopedic conditions that limit physical activity or make exercise testing unsafe
  • Currently pregnant, planning pregnancy during the study period, or less than 6 months postpartum
  • Use of medications known to affect glucose metabolism, heart rate, or physical activity (e.g., beta-blockers, insulin)
  • Diagnosed severe mental health disorders that would impair study participation
  • Participation in another clinical trial or lifestyle intervention within the past 3 months
  • Inability or unwillingness to attend lab visits or comply with the intervention protocol
University of Wisconsin, River Falls logoUniversity of Wisconsin, River Falls
Study Responsible Party
Gregory Ruegsegger, Principal Investigator, Professor, University of Wisconsin, River Falls
No contact data.
1 Study Locations in 1 Countries

Wisconsin

University of Wisconsin-River Falls, River Falls, Wisconsin, 54022, United States